ASCO: Herceptin Still a Boon for Small Breast Tumors

“ASCO: Herceptin Still a Boon for Small Breast Tumors.” By Michael Smith, MedPage Today.

The monoclonal antibody trastuzumab (Herceptin) was beneficial for women with small tumors, according to a new meta-analysis of the randomized trials of the drug. It also was equally beneficial in hormone receptor-positive and -negative disease, according to Ciara O’Sullivan, MD, of the National Cancer Institute in Bethesda, Md.

O’Sullivan’s group performed a patient-level analysis of participants in five of the six major trials to compare the efficacy of trastuzumab versus no trastuzumab in women with small HER2-positive tumors. The primary endpoints were disease-free and overall survival and the analysis was done separately for women who were hormone receptor-positive and -negative. The findings appear to settle a question raised by the original pivotal trials — whether the drug was beneficial in women with tumors 2 cm or less in size, O’Sullivan said at the American Society of Clinical Oncology annual meeting.

More ยป

Be Sociable, Share!

Articles & Posts